大行评级 | 大和：首予康方生物“买入”评级予目标价39港元

金融界网站2022-11-14

格隆汇11月14日丨大和发表研报，首予康方生物(0026.HK)“买入”评级，目标价39港元，认为公司首创双特异性抗体新药依沃西(AK112)和新型肿瘤免疫治疗新药卡度尼利(AK104)将成为该股未来12个月的强劲催化。报告指，康方生物现时拥有２种已上市的免疫疗法，包括Pulocinab(PD-mAb)和Cadonilimab(PD-1 x CTLA-4-4bsAb)。　　Cadonilimab将...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2283247394?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-11-14 14:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2283247394","market":"hk","top_or_hot":-1,"title":"大行评级 | 大和：首予康方生物“买入”评级 予目标价39港元","media":"金融界网站","content":"<div>\n<p>格隆汇11月14日丨大和发表研报，首予康方生物(0026.HK)“买入”评级，目标价39港元，认为公司首创双特异性抗体新药依沃西(AK112)和新型肿瘤免疫治疗新药卡度尼利(AK104)将成为该股未来12个月的强劲催化。报告指，康方生物现时拥有２种已上市的免疫疗法，包括Pulocinab(PD-mAb)和Cadonilimab(PD-1 x CTLA-4-4bsAb)。　　Cadonilimab将...</p>\n\n<a href=\"http://hk.jrj.com.cn/2022/11/14143637136717.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大行评级 | 大和：首予康方生物“买入”评级 予目标价39港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大行评级 | 大和：首予康方生物“买入”评级 予目标价39港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-14 14:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://hk.jrj.com.cn/2022/11/14143637136717.shtml><strong>金融界网站</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇11月14日丨大和发表研报，首予康方生物(0026.HK)“买入”评级，目标价39港元，认为公司首创双特异性抗体新药依沃西(AK112)和新型肿瘤免疫治疗新药卡度尼利(AK104)将成为该股未来12个月的强劲催化。报告指，康方生物现时拥有２种已上市的免疫疗法，包括Pulocinab(PD-mAb)和Cadonilimab(PD-1 x CTLA-4-4bsAb)。　　Cadonilimab将...</p>\n\n<a href=\"http://hk.jrj.com.cn/2022/11/14143637136717.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"http://hk.jrj.com.cn/2022/11/14143637136717.shtml","article_id":"2283247394","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2283247394","pubTimestamp":1668407791,"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"格隆汇11月14日丨大和发表研报，首予康方生物“买入”评级，目标价39港元，认为公司首创双特异性抗体新药依沃西和新型肿瘤免疫治疗新药卡度尼利将成为该股未来12个月的强劲催化。报告指，康方生物现时拥有２种已上市的免疫疗法，包括Pulocinab和Cadonilimab。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"09926":"康方生物"},"translate_title":"Big bank rating Daiwa: The first \"buy\" rating of Kangfang Bio was given to the target price of HK $39","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"格隆汇11月14日丨大和发表研报，首予康方生物(0026.HK)“买入”评级，目标价39港元，认为公司首创双特异性抗体新药依沃西(AK112)和新型肿瘤免疫治疗新药卡度尼利(AK104)将成为该股未来12个月的强劲催化。报告指，康方生物现时拥有２种已上市的免疫疗法，包括Pulocinab(PD-mAb)和Cadonilimab(PD-1 x CTLA-4-4bsAb)。　　Cadonilimab将成为首个在中国上市的下一代免疫疗法，或基于PD-1的双特异性抗体，相信该疗法拥有实现数十亿元的销售潜力，并在多个适应症上具临床益处，已有资格参与即将举行的国家医保谈判，认为这将成为销售飙升的好兆头。　　报告认为，集团自研的AK112具差异化安全性的特征，同时临床试验结果正面，有利于正在进行的第三期试验，预计该药在2030年用于两个适应症上的经风险调整的销售额能达20亿元人民币，又认为AK102的潜在合作伙伴将有助降低AK112全球开发时过程中的风险事件。　　报告同时预测，集团的尾期项目AK102和AK101将于2024年中旬发布。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2283247394"}

大行评级 | 大和：首予康方生物“买入”评级 予目标价39港元

精彩评论

大行评级 | 大和：首予康方生物“买入”评级予目标价39港元